Data published in The Lancet Oncology found that a hypofractionated radiation schedule of 55 Gy in 20 fractions is noninferior to a schedule of 64 Gy in 32 fractions for patients with this disease.
Continued approval for durvalumab in previously treated adult patients with locally advanced or metastatic bladder cancer was dependent upon results from the phase 3 DANUBE trial in the first-line metastatic bladder cancer setting, which did not meet its primary end points in 2020.
The biologics license application is for the locally administered fusion protein Vicineum for the treatment of high-risk, bacillus Calmette-Guérin (BCG)–unresponsive non-muscle invasive bladder cancer.